Reversing insulin resistance with AI-driven lifestyle modification. Vitadio develops prescription digital therapeutics (DTx) that treat the root causes of cardiometabolic disease—starting with type 2 diabetes and prediabetes—by combining evidence-based medicine, behaviour change techniques, and proprietary AI to deliver personalised diet and lifestyle guidance.

Vitadio is provided as a Class I medical device under MDR and is ISO 27001 and GDPR compliant. The platform offers AI-driven real-time dietary feedback, personalised goals and smart nudges, plus proactive human support from in-app networks and dietitians. Multiple independent, peer-reviewed studies report clinically meaningful outcomes including HbA1c reduction, substantial weight loss, and improved self-management.

Founded in 2019 by four founders and headquartered in Prague and Berlin, Vitadio is available across several European countries and is reimbursed by statutory health insurers in Germany. The company partners with healthcare providers and pharmaceutical organisations to augment pharmacotherapy and improve long-term cardiometabolic outcomes.

Vitadio is hiring across product, engineering and clinical roles. For job openings visit the careers page or contact the team via [email protected].